| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Jun, 2024 |
| Sales | 767,610 | 658,550 | 686,520 | 642,330 | 624,550 |
| Sales Growth | +16.56% | -4.07% | +6.88% | +2.85% | -5.67% |
| Net Income | 299,610 | 259,740 | 240,290 | 289,440 | 196,080 |
| Net Income Growth | +15.35% | +8.09% | -16.98% | +47.61% | -16.40% |
Shionogi & Ltd Un ADR (SGIOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
Fiscal Year End Date: 03/31